Day: March 30, 2022

Proportion of Overseas Business Exceeds 30% for the First Time

Risk of symptomatic COVID-19 was reduced by 71% compared to placebo in pre-exposure prophylaxis and 75% compared to placebo in post-exposure prophylaxis

Risk of hospitalization or death in participants with mild to moderate COVID-19 was reduced by 66% compared to placebo in the primary efficacy analysis population and by 77% compared to placebo in participants who received treatment within three days of symptom onset

Full year and fourth quarter 2021 financial results reported; $591 million in cash and investments expected to be sufficient to fund operations into second half of 2024

WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, reported that the primary endpoints were met with statistical significance for all three indications in the company’s ongoing global Phase 2/3 clinical trials evaluating its investigational drug adintrevimab (ADG20) as a pre-and-post-exposure prophylaxis (EVADE) and treatment (STAMP) for COVID-19. EVADE and STAMP were primarily conducted during a time when pre-Omicron SARS-CoV-2 variants were dominant. Following the emergence of the Omicron variant, in a pre-specified exploratory analysis in a subset of the pre-exposure cohort, a clinically meaningful reduction in cases of symptomatic COVID-19 was observed with adintrevimab compared to placebo. Across both trials, a single intramuscular (IM) administration of adintrevimab at the 300mg dose had a similar safety profile to that of placebo. Based on these data, Adagio plans to engage with the U.S. Food and Drug Administration (FDA) and to submit an Emergency Use Authorization (EUA) application in the second quarter of 2022 for adintrevimab for both the prevention and treatment of COVID-19.

In addition, Adagio provided an update on its ongoing Phase 1 study evaluating adintrevimab at higher doses and on research activities related to adintrevimab re-engineering and the identification of new antibodies to potentially address COVID-19 and other viruses.

“COVID-19 continues to pose significant challenges globally as waning immunity combined with the emergence of resistant variants has led to ongoing waves of disease. We believe that a suite of options – spanning prophylaxis and treatment – is needed to effectively address this virus as it continues to evolve, and these data give us confidence in the potential role adintrevimab can play in physicians’ arsenals,” said David Hering, MBA, interim chief executive officer and chief operating officer of Adagio. “Based on the data from both EVADE and STAMP, including the impacts observed in preliminary analyses from participants enrolled after the emergence of the Omicron variant, our team is initiating discussions with the FDA and preparing an EUA submission for adintrevimab. With more than one million doses of adintrevimab secured for 2022 and a solid financial position expected to take us into the second half of 2024, we are optimistic about the road ahead and the impact adintrevimab could have for the many people around the globe, particularly those at high risk with co-morbidities, who continue to need options.”

Michael Ison, M.D., M.S., professor of Medicine in the Division of Infectious Diseases and of Surgery in the Division of Organ Transplantation, Northwestern University Feinberg School of Medicine, added, “the compelling data generated on adintrevimab in both of Adagio’s clinical trials represent an important step toward further addressing the continuation of the COVID-19 pandemic. I am particularly encouraged by the consistent treatment effect observed across all three clinical settings and patient subpopulations, and the favorable safety profile, with just a single dose and convenient IM delivery for all patients. The risk-reduction in the post-exposure prophylaxis setting regardless of serostatus translates to real-world use when clinicians might not know the vaccination or prior infection status of their patients. In the STAMP trial, adintrevimab showed prevention of hospitalization and death in the face of the ‘highest-risk’ variant (Delta) to-date.”

EVADE Preliminary Data
EVADE is a global, multi-center, double-blind, placebo-controlled Phase 2/3 clinical trial evaluating adintrevimab at the 300mg IM dose in two independent cohorts for the prevention of COVID-19. The study includes a pre-exposure prophylaxis (PrEP) cohort and a post-exposure prophylaxis (PEP) cohort. The study population is comprised of adults and adolescents at risk of SARS-CoV-2 infection due to reported recent exposure or whose circumstances placed them at increased risk of acquiring SARS-CoV-2 infection and developing symptomatic COVID-19.

In the primary efficacy analysis of the PrEP cohort, adintrevimab was associated with a lower incidence of symptomatic COVID-19 compared with placebo through month three or the emergence of Omicron, whichever was earlier (12/730, 1.6% vs. 40/703, 5.7%, respectively). The standardized risk difference was -4.0% (95% CI –6.0, -2.1; p <0.0001), demonstrating a 71% relative risk reduction in favor of adintrevimab through three months. There were five (0.7%) COVID-19 related hospitalizations in the placebo group compared to none in the adintrevimab group. In a pre-specified exploratory analysis of the PrEP cohort, which included 402 participants (196 and 206 in the adintrevimab and placebo groups, respectively) following the emergence of Omicron (BA.1), a clinically meaningful reduction in cases of symptomatic COVID-19 was observed with adintrevimab, as compared to placebo. Adintrevimab was associated with a relative risk reduction of 59% and 47% with a median follow-up duration of 56 and 77 days, respectively (nominal p <0.05).

In the primary efficacy analysis in the PEP cohort, adintrevimab met statistical significance and was associated with a lower incidence of symptomatic COVID-19 through day 28 compared with placebo (3/173, 1.7% vs. 12/175, 6.9%, respectively). The standardized risk difference was -4.9% (95% CI: -8.8, -1.0; p=0.0135), demonstrating a 75% relative risk reduction in favor of adintrevimab through 28 days. There were two (1.1%) COVID-19 related hospitalizations in the placebo group compared to none in the adintrevimab group.

In the EVADE cohorts across 1,239 adintrevimab-treated participants with a median range of follow up of 140 days for the PrEP cohort and 126 days for the PEP cohort as of the March 2, 2022, data cut off, the safety profile was similar to that of placebo. The incidence of adverse events (AEs), including serious adverse events (SAEs), was similar between adintrevimab and placebo groups. No study drug related SAEs, including deaths, were reported. The most frequently reported AEs were injection-site reactions, the majority of which were mild or moderate in severity and occurred with similar frequency in both groups.

STAMP Preliminary Data
STAMP is a global, multi-center, double-blind, placebo-controlled Phase 2/3 clinical trial evaluating adintrevimab at the 300mg IM dose in patients with mild to moderate COVID-19 who are at high risk for disease progression. Adintrevimab was associated with a statistically significant lower incidence of COVID-19 related hospitalization or all cause death through day 29 compared with placebo (8/169, 4.7% vs. 23/167, 13.8%), with a standardized risk difference of -8.6% (95% CI: -14.65, -2.57; p=0.0052), demonstrating a 66% relative risk reduction in favor of adintrevimab. There was one death (0.6%) in the adintrevimab group, compared with six deaths (3.6%) in the placebo group through day 29. In patients treated within three days of symptom onset (adintrevimab n=91, placebo n=85), adintrevimab reduced the risk of COVID-19 hospitalization or death from any cause by 77% compared to placebo. STAMP enrolled 63 participants (29 in the adintrevimab group and 34 in the placebo group) with COVID-19 infection with the Omicron SARS-CoV-2 variant. There were two events of COVID-19 related hospitalization and no deaths through day 29 among the patients with the Omicron variant, and both events of hospitalization occurred in the placebo group.

In STAMP, across 192 adintrevimab-treated participants with a median follow up of 73 days in the adintrevimab group as of the February 2, 2022, data cut off, the incidence of AEs, including SAEs, was lower in the adintrevimab group. No study drug related SAEs, including deaths, were reported. The most frequently reported AEs were injection-site reactions, all of which were mild or moderate in severity and occurred with similar frequency in both groups.

“On behalf of the entire Adagio team, I’d like to thank the numerous investigators, clinical teams and, most importantly, the patients, families and caregivers for their participation in our clinical trials. We are encouraged by the data and look forward to submitting an EUA and discussing these results with the FDA and other regulatory authorities. Further, we are continuing our research efforts to improve adintrevimab activity against Omicron and identify antibodies targeting novel domains, which will provide potential additional product candidates to take into clinical development. Collectively, these efforts showcase the ability of our platform and expertise to discover, design and engineer novel antibodies, and execute global clinical trials, to potentially address infectious diseases,” said Ellie Hershberger, Pharm.D., chief development officer of Adagio.

Additional Development and Research Updates
Adagio continues to leverage its platform and expertise by conducting numerous efforts to address COVID-19, other coronaviruses, influenza and other infectious diseases, including:

• Advancing a Phase 1 trial in healthy volunteers to evaluate pharmacokinetics and safety of additional higher doses of adintrevimab to supplement the data generated to date, which has evaluated doses up to 600mg IM. Preliminary safety data through two weeks post-dosing suggest a favorable safety profile at the 1200mg dose administered with IM injection or intravenously (IV).
• Ongoing efforts to modify adintrevimab to improve binding to the Omicron subvariants (BA.1 and BA.2) in order to enhance neutralization potency while retaining the broad neutralization observed in vitro against other SARS-CoV-2 variants of concern. Re-engineered variants of ADG20 show over 100-fold improvement in binding and up to 40-fold enhanced neutralizing activity against the Omicron BA.1 variant while maintaining activity against all other variants of concern tested to date.
• Ongoing discovery efforts to assess additional monoclonal antibodies from the company’s proprietary library of previously isolated SARS-CoV-2 antibodies for neutralization breadth and potency, which could be developed as a standalone treatment or combination therapy. Novel antibodies isolated from Omicron breakthrough infection donors have displayed in vitro activity against the 2003 SARS virus and all SARS-CoV-2 variants of concern tested to date, including the BA.1 and BA.2 variants.
• Continuing discovery efforts to identify novel, broadly neutralizing antibodies that target epitopes both within and outside the receptor binding domain of SARS-CoV-2 and pan betacoronavirus neutralizing antibodies.

Full Year and Fourth Quarter 2021 Financial Results

• Cash Position and Financial Guidance: Cash, cash equivalents and marketable securities were $591.4 million as of December 31, 2021. Based on current operating plans, Adagio expects its existing cash, cash equivalents and marketable securities will enable the company to fund its operating expenses and capital expenditure requirements into the second half of 2024.
• R&D Expenses: Research and development (R&D) expenses, including in-process research and development expenses, were $68.4 million for the quarter ended December 31, 2021, and $190.4 million for the year ended December 31, 2021.
• SG&A Expenses: Selling, general and administrative (SG&A) expenses were $14.7 million for the quarter ended December 31, 2021, and $36.5 million for the year ended December 31, 2021.
• Net Loss: Net loss was $83.0 million, or $0.77 basic and diluted net loss per share, for the quarter ended December 31, 2021, and $226.8 million, or $5.32 basic and diluted net loss per share, for the year ended December 31, 2021.

About Adintrevimab
Adintrevimab (ADG20), Adagio’s lead product candidate, is designed to be a potent, broadly neutralizing antibody for both the prevention and treatment of COVID-19, including disease caused by most variants, as either a single or combination agent. Adintrevimab is being assessed in two separate Phase 2/3 clinical trials: the EVADE trial for the prevention of COVID-19 in both the post-exposure and pre-exposure settings, and the STAMP trial for the treatment of COVID-19. Preliminary data from these trials demonstrated that in the pre-Omicron population, adintrevimab met the primary endpoints across all three indications, demonstrating statistically significant and clinically meaningful efficacy. Across each of the trials, intramuscular (IM) administration of adintrevimab at the 300mg dose had a similar safety profile to that of placebo. Adintrevimab is also being evaluated in a Phase 1 study to evaluate safety and pharmacokinetics at higher doses, and as of an interim data cut, no study drug related adverse events, serious adverse events, injection-site reactions or hypersensitivity reactions were reported across all dose levels evaluated. Adintrevimab is an investigational monoclonal antibody that is not approved for use in any country. The safety and efficacy of adintrevimab have not been established.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases. The company is developing its lead product candidate, adintrevimab, for the prevention and treatment of COVID-19, the disease caused by the virus SARS-CoV-2 and its variants. Beyond COVID-19, Adagio is leveraging robust antibody discovery and development capabilities that have enabled expedited advancement of adintrevimab into clinical trials to develop therapeutic or preventative options for other infectious diseases, such as additional coronaviruses and influenza. Adintrevimab is an investigational monoclonal antibody that is not approved for use in any country. The safety and efficacy of adintrevimab have not been established. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “could”, “expects,” “intends,” “potential”, “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of adintrevimab, the review and analysis of data from our ongoing trials and the timing thereof, the initiation, modification and completion of studies or trials and related preparatory work, and our research and development programs; our plans related to engaging with regulatory authorities, including the timing of any regulatory submissions or applications; our pursuit of other strategies to broaden our portfolio of SARS-CoV-2 mAbs to address other SARS-CoV-2 variants of concern, including the Delta and Omicron variants; our discovery efforts to identify novel broadly neutralizing antibodies that target distinct epitopes both within and outside the receptor binding domain of SARS-CoV-2 and other beta coronaviruses; our expected cash runway; and other statements that are not historical fact. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the impacts of the COVID-19 pandemic on our business and those of our collaborators, our clinical trials and our financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, the predictability of clinical success of adintrevimab based on neutralizing activity in pre-clinical studies, variability of results in models used to predict activity against SARS-CoV-2 variants of concern, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, and the uncertainties and timing of the regulatory approval process, including the outcome of our discussions with regulatory authorities concerning our Phase 2/3 clinical trials and the result of any emergency use application submission. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in Adagio’s Form 10-Q for the quarter ended September 30, 2021 filed with the Securities and Exchange Commission (the “SEC”), and in our other filings with the SEC, and in Adagio’s future reports to be filed with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic.  Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts
Media Contact:
Dan Budwick, 1AB
dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

ADAGIO THERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(In thousands, except share and per share amounts)

		December 31,
			2021				2020
Assets
Current assets:
Cash and cash equivalents		$	542,224			$	114,988
Marketable securities			49,194				—
Prepaid expenses and other current assets			25,293				2,394
Total current assets			616,711				117,382
Property and equipment, net			83				—
Other non-current assets			3,297				—
Total assets		$	620,091			$	117,382
Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable		$	5,783			$	8,153
Accrued expenses			56,277				4,919
Total current liabilities			62,060				13,072
Early-exercise liability			6				11
Other non-current liabilities			6				—
Total liabilities			62,072				13,083
Commitments and contingencies
Convertible preferred stock (Series A, B and C), $0.0001 par value; no shares authorized, issued and outstanding at December 31, 2021; 12,647,934 shares authorized, issued and outstanding at December 31, 2020; aggregate liquidation preference of $0 and $169,900 at December 31, 2021 and December 31, 2020, respectively			—				169,548
Stockholders’ equity (deficit):
Preferred stock (undesignated), $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding at December 31 2021; no shares authorized, issued and outstanding at December 31, 2020			—				—
Common stock, $0.0001 par value; 1,000,000,000 shares authorized, 111,251,660 shares issued and 110,782,909 shares outstanding at December 31, 2021; 150,000,000 shares authorized, 28,193,240 shares issued and 5,593,240 shares outstanding as of December 31, 2020			11				1
Treasury stock, at cost; 468,751 shares and 22,600,000 shares at December 31, 2021 and December 31, 2020, respectively			—				(85	)
Additional paid-in capital			850,125				154
Accumulated other comprehensive loss			(8	)			—
Accumulated deficit			(292,109	)			(65,319	)
Total stockholders’ equity (deficit)			558,019				(65,249	)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)		$	620,091			$	117,382

ADAGIO THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
(In thousands, except share and per share amounts)

		Year Ended December 31, 2021				Period from June 3, 2020 (Inception) to December 31, 2020
Operating expenses:
Research and development(1)		$	182,891			$	21,992
Acquired in-process research and development(2)			7,500				40,125
Selling, general and administrative			36,517				3,210
Total operating expenses			226,908				65,327
Loss from operations			(226,908	)			(65,327	)
Other income (expense):
Other income (expense), net			118				8
Total other income (expense), net			118				8
Net loss			(226,790	)			(65,319	)
Other comprehensive income (loss):
Unrealized loss on available-for-sale securities, net of tax			(8	)			—
Comprehensive loss		$	(226,798	)		$	(65,319	)
Net loss per share attributable to common stockholders, basic and diluted		$	(5.32	)		$	(18.10	)
Weighted-average common shares outstanding, basic and diluted			42,621,265				3,608,491

(1)  Includes related-party amounts of $4,150 for the year ended December 31, 2021 and $595 for the period from June 3, 2020 (inception) to December 31, 2020.
(2)  Includes related-party amounts of $7,500 for the year ended December 31, 2021 and $39,915 for the period from June 3, 2020 (inception) to December 31, 2020.

TEMECULA, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (“Group”), a part of the Nikkiso Co., Ltd (Japan) group of companies, is pleased to announce that Umit Ciftci has been named Regional Business Development Manager for Turkey and the surrounding areas.

Based in Istanbul Turkey, he will be responsible for the Group’s full product line, and will report to Ole Jensen, NCE&IG GmbH Germany.

Umit received a degree in Management Engineering, which provided a solid background in engineering as well as business and finance. He has over 25 years of experience in Compressed Air working at various positions including sales engineer, marketing and business line manager in Turkey and Business Development Manager in UAE for Atlas Copco.

“Umit’s experience, as well as market and industry knowledge will be of great benefit to NCEIG GmbH, as we work to develop the potential opportunities in this market. We look forward to his positive contributions,” according to Ole Jensen, Vice President NCEIG Europe.

With this addition, Nikkiso continues their commitment to be both a global and local presence for their customers.

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture engineered cryogenic gas processing equipment and small-scale process plants for the liquefied natural gas (LNG), well services and industrial gas industries. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Cosmodyne and Cryoquip and a commonly controlled group of approximately 20 operating entities.

For more information please visit www.nikkisoCEIG.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

Tecnologia de percepção ambiental para uma condução autônoma mais segura com detecção melhor

QUEBEC CITY, March 29, 2022 (GLOBE NEWSWIRE) — A LeddarTech^®, líder global no fornecimento da tecnologia de detecção ADAS e AD mais flexível, robusta e precisa, tem o prazer de anunciar sua participação na Automotive Tech.AD Berlin no Titanic Chaussee Hotel Berlin como expositora e palestrante principal.

4-5 de abril de 2022: LeddarVision™ Demonstrator Space da LeddarTech (ao vivo e virtual)

Junte-se à equipe da LeddarTech para demonstrações reais de LeddarVision. O único software de fusão e percepção de sensores que usa fusão de dados brutos para simplificar conjuntos de sensores complexos, eliminar a dependência de hardware e fornecer aos clientes a flexibilidade de soluções de escala rápida em todos os modelos de veículos, proporcionando maior desempenho de ADAS e AD.

Conheça o CTO da LeddarTech, Pierre Olivier, pioneiro em sensoriamento com mais de 30 anos de experiência que fará apresentações nesses eventos durante a conferência:

• Domingo, 3 de abril de 2022, 19h45 – 23h CET: Sessão Informal

Tema: O Caminho para a Automação Plena – Progresso e Desafios

• Segunda-feira, 4 de abril de 2022, 10h – 10h30 CET: Apresentação

Tema: Tecnologia de Detecção e Percepção – Soluções que Resolvem Desafios Críticos de Detecção

Conheça a LeddarVision, uma plataforma de fusão e percepção de sensores de dados brutos que gera um modelo ambiental 3D RGBD abrangente com suporte a múltiplos sensores para configurações de câmera, radar e LiDAR. Esta solução centrada em software oferece desempenho de percepção superior por meio de planejamento de caminho, detecção de espaço livre e detecção, rastreamento e classificação aprimorados de objetos.

Sobre a Automotive Tech.AD Berlin

A Tech.AD Europe estimula você com novas ideias, conexões e inspiração. Este evento é dirigido a engenheiros e especialistas automotivos avançados de OEMs, fornecedores de soluções e institutos de pesquisa líderes com foco na aprendizagem de máquina AI +, tecnologias de percepção e sensor, arquiteturas de software e plataformas AV, testes e validação, veículos comerciais e implantação antecipada, conectividade e 5G, infraestruturas e cidades inteligentes, segurança e proteção, e muito mais. Junte-se a mais de 500 dos especialistas e executivos de veículos autônomos técnicos mais influentes em Berlim e online! Participe do evento também juntamente com a LeddarTech pessoalmente ou de forma digital registrando-se hoje mesmo no https://www.autonomous-driving-berlin.com/.

Sobre a LeddarTech

Fundada em 2007, a LeddarTech é uma empresa abrangente de sensoriamento ambiental completo, que viabiliza que os clientes resolvam desafios essenciais de sensoriamento, fusão e percepção em toda a cadeia de valor. A LeddarTech fornece soluções de percepção escaláveis econômicas de Nível 2+ ADAS ao Nível 5 de plena autonomia com LeddarVision™, uma plataforma de fusão e percepção de sensores de dados brutos que gera um modelo ambiental 3D abrangente a partir de uma variedade de tipos e configurações de sensores. A LeddarTech também dá suporte aos fabricantes LiDAR e integradores de sistemas automotivos de Nível 1-2 com o LeddarSteer™ de direção de feixe digital e o LiDAR XLRator™, uma solução para desenvolvimento LiDAR de estado sólido de grau automotivo com base na LeddarEngine™, e componentes principais de parceiros globais de semicondutores. A empresa é responsável por muitas inovações de aplicações com sensor remoto automotivos e de mobilidade avançadas, com mais de 100 tecnologias ADAS aprimoradas patenteadas (concedidas ou pendentes), e capacidade de condução autônoma.

Para mais informação sobre a LeddarTech, visite www.leddartech.com, LinkedIn, Twitter, Facebook e YouTube.

Contato:
Daniel Aitken, Vice-Presidente, Marketing Global, Comunicações e Relacionamento com o Investidor, LeddarTech Inc.
Tel.: + 1-418-653-9000 ramal 232
daniel.aitken@leddartech.com

Contato de Relações com Investidores: InvestorRelations@leddartech.com
https://investors.leddartech.com/

Os logotipos Leddar, LeddarTech, LeddarSteer, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, LeddarEcho, VAYADrive, VayaVision, XLRator e afins são marcas comerciais ou marcas comerciais registradas da LeddarTech Inc. e suas subsidiárias. Todas as outras marcas e nomes de produtos são ou podem ser marcas comerciais ou marcas comerciais registradas usadas para identificar produtos ou serviços de seus respectivos proprietários.

The Prize’s 44th session awards eminent figures in each of its Arabic Language & Literature and Service to Islam categories

Riyadh, March 29, 2022 (GLOBE NEWSWIRE) — Two mathematicians and a scientist were among this year’s King Faisal Prize’s seven laureates who received their prizes on 29 March in Riyadh, Saudi Arabia, for having enriched humanity with key and invaluable achievements and discoveries, and excelled in the fields of Medicine, Science, Arabic Language & Literature, and Serving to Islam.

The Medicine Prize was awarded to Professor David Liu, Richard Merkin Professor and Director of the Merkin Institute of Transformative Technologies in Healthcare, who invented the first gene “base editor” in 2016.

This technology laid the foundation for possibly treating thousands of genetic diseases like sickle cell disease and muscular dystrophy. Professor David Liu used “base editors” in mice to correct the genetic mutation behind progeria, a rare condition characterized by premature aging, retarded development, and early death. Still, more work needs to be done before gene “base editors” can be used in humans.

Initiating a revolution in genome editing, “base editors” have received great global demand. They were distributed over 9,000 times to more than 3,000 laboratories around the world. Scientists were able to publish more than 300 papers on this technique, used in different organisms ranging from bacteria to mice.

“Base editing” is a precise genome editing method; like a genetic pencil, that rewrites DNA base letters, which cause genetic mutations and potentially genetic diseases. This technology, which is in constant development, chemically rewrites one DNA base to another by rearranging the atoms of one DNA base to resemble a different base. In 2019, Professor David Liu created with his team “prime editing” which offers more targeting flexibility and greater editing precision.

With over 75 issued U.S. patents, Professor Liu was referred to as the “Gene Corrector” by Nature magazine topping its list of “Ten People Who Mattered This Year” in 2017 and was included in the “Foreign Policy Leading Global Thinkers list”. He is also a biotech entrepreneur, cofounding “Editas Medicine”, which uses CRISPR therapies (tool for editing genomes) to “discover, develop, manufacture, and commercialize transformative, durable, and precise genomic medicines for a broad class of diseases”.

The Science Prize (Mathematics) was awarded jointly to Professor Martin Hairer, Chair in Probability and Stochastic Analysis at Imperial College’s Department of Mathematics, and to Professor Nader Masmoudi, a distinguished Professor of Mathematics at the New York University of Abu Dhabi and head of his Research Center on Stability, Instability and Turbulence.

Professor Martin Hairer developed the theory of regularity structures which gave a precise mathematical meaning to several equations that were previously outside the scope of mathematical analysis. He published his theory in 2014 providing tools and manuals for solving many previously incomprehensible equations called the stochastic partial differential equations (SPDEs). These equations involve chance and describe how randomness throws disorder into different phenomena like coin tossing, stock price changes, wind movement in a tunnel, or forest fire growth. He transformed the area of SPDEs by introducing fundamental new techniques and was able to solve equations like KPZ equation which describes the evolution of the boundary at which two substances meet over time.

Professor Hairer is a world leader in probability theory and analysis and has authored a monograph and over 100 research articles. His work has been distinguished with several prizes and awards, most notably the LMS Whitehead and Philip Leverhulme prizes in 2008, the Fermat prize in 2013, the Fröhlich prize and the Fields Medal in 2014, a knighthood in 2016, and the Breakthrough prize in Mathematics in 2020.

As for Professor Nader Masmoudi, he was able to unlock the mystery around many physics problems which remained unsolved for centuries. He found a flaw in “Euler’s” mathematical equations which for more than two centuries described the motions of fluids under any circumstance. He discovered that Euler’s equations do not apply to all circumstances, as previously thought, and proved that they could break or fail under certain conditions related to fluids. His work helped solve and understand many problems related to fluid-modeling like weather predictions and airplane turbulence.

For the past 20 years, Professor Masmoudi’s research has been at the forefront of Partial Differential Equations, Fluid Mechanics, and Dynamical Systems. He has been cited by more than 8000 papers for his works in pure and applied mathematics. He has been recognized with numerous awards, including the Best Scientific Paper Award in Annales de l’Institue Henri Poincaré, a Chair from the Fondation Sciences Mathematiques de Paris, The Fermat Prize, and the Chair Schlumberger from the IHES in Paris.

In addition to Medicine and Science, King Faisal Prize recognized this year the achievements of outstanding thinkers and scholars in the field of Arabic Language & Literature, and honored exemplary leaders who played a pivotal role in serving Islam, Muslims, and humanity at large.

The Arabic Language and Literature Prize about “Arabic Literature Studies in English” was awarded to Professor Suzanne Stetkevych, Chair of the Department of Arabic & Islamic Studies at Georgetown University, and to Professor Muhsin Al-Musawi, Professor of Arabic and Comparative Literary Studies at Columbia University.

Professor Suzanne Stetkevych was awarded the prize for her extensive research and work analyzing Arabic literature with unmatched depth from the pre-Islamic period to the revivalist period. Her research approach resulted in the renewal of the critical perspective and methods of studying classical Arabic poetry.

Professor Muhsin Al-Musawi received the prize for being a well-established authority in the field of Arabic literature demonstrating his encyclopedic knowledge in both classical and modern Arabic literature. His research and studies have made great impact on students and researchers in the field of Arabic studies, both in the Arab world and the West. He handled Arabic literature as a world literature.

The Service to Islam Prize was awarded to the former Tanzanian President His Excellency Ali Hassan Mwinyi and to Professor Hassan Mahmoud Al Shafei. His Excellency Ali Hassan Mwinyi actively participated in Islamic advocacy, spreading the spirit of religious tolerance, educating Muslims, and translating many Islamic resources and references into Swahili language. In parallel, Professor Hassan Mahmoud Alshafei served Islamic sciences through teaching, writing, authenticating, and translating, and has contributed to the establishment of the International Islamic University in Islamabad and the development of its colleges’ curricula.

The Islamic Studies Prize for this year on “Islamic Heritage of Al- Andalus” was withheld because the nominated works did not meet the criteria of the prize.

Since 1979, King Faisal Prize in its 5 different categories has awarded 282 laureates from 44 different nationalities who have made distinguished contributions to different sciences and causes. Each prize laureate is endowed with USD 200 thousand; a 24-carat gold medal weighing 200 grams, and a Certificate inscribed with the Laureate’s name and a summary of their work which qualified them for the prize.

Attachments

• King Faisal Prize Award Ceremony 2022
• King Faisal Prize Award Ceremony 2022 

Maysa Shawwa
King Faisal Prize
00966581747005
Maysa.Shawwa@kff.com

Varejista Multimídia Oferece Solução PicStorage Cloud para Milhões de Clientes

BRIDGEWATER, N.J., March 29, 2022 (GLOBE NEWSWIRE) — A Synchronoss Technologies, Inc. (“Synchronoss” ou a “Empresa”) (Nasdaq: SNCR), líder global e inovadora em nuvem, mensagens e produtos e plataformas digitais, anunciou hoje que a Kitamura, principal varejista de multimídia do Japão, lançou uma versão de marca branca na nuvem pessoal Synchronoss com o nome PicStorage.

A Kitamura é uma das principais varejistas do Japão que oferece serviços e produtos relacionados à imagem, incluindo câmeras, impressão de fotos, dublagem de vídeos, estúdio de fotos, álbuns de fotos e mais. A empresa tem mais de 1.000 lojas em todo o país, com mais de 20 milhões de visitantes pagantes a cada ano e aproximadamente 10 milhões de consumidores registrados nos seus serviços online. Com essa integração, a Kitamura poderá fornecer uma experiência online e de varejo perfeita, com a nova oferta de nuvem pessoal de marca branca.

“Além das nossas parcerias com operadoras e provedores de serviços, a Synchronoss está explorando novos aplicativos para a nossa plataforma na nuvem”, disse Yosuke Morioka, Gerente Geral da Synchronoss Japan. “Nossa colaboração com a Kitamura e o lançamento do PicStorage é apenas um exemplo de como a Synchronoss Personal Cloud pode ser aproveitada como um serviço de valor agregado em vários setores e verticais. “

A Kitamura oferecerá o PicStorage como um serviço por assinatura. Ele incluirá um aplicativo de marca e acesso a um portal online para armazenamento, gerenciamento e compartilhamento de conteúdo digital.

“O lançamento do PicStorage é uma extensão perfeita do nosso portfólio de produtos e serviços”, disse Hajime Yanagisawa, Diretor Digital e Diretor Administrativo da Kitamura. “Atualmente, milhões dos nossos clientes poderão proteger seus conteúdos digitais na nuvem e compartilhá-los com amigos e familiares. O PicStorage permite que o cliente experimente novas maneiras de organizar e curtir suas fotos e memórias. A Kitamura continuará a expandir este serviço com serviços relacionados a fotos que melhorarão a experiência do cliente.”

Além da Kitamura, a Synchronoss tem clientes nos EUA, Europa e Ásia, incluindo Verizon, AT&T, Tracfone, Assurant, Allstate Protection Plans, Telkomsel, BT, Proximus e SFR.

Sobre a Kitamura
A Kitamura é uma empresa líder em produtos e serviços fotográficos e relacionados a vídeos do Japão. A empresa possui os maiores laboratórios internos do Japão (fábricas de processamento de fotos e vídeos) e fornece seus serviços e produtos por meio de mais de 1.000 lojas de varejo em todo o país e online. A empresa tem por missão fornecer serviços para moldar as lembranças dos clientes, no presente momento e também nas próximas décadas, restaurar fotos e reviver memórias preciosas.

Sobre a Synchronoss

A Synchronoss Technologies(Nasdaq: SNCR) cria software que capacita empresas ao redor do mundo a se conectarem com seus assinantes de forma confiável e significativa. O conjunto de produtos da empresa ajuda a agilizar as redes, simplificar a integração e envolver os assinantes, permitindo novos fluxos de receita, redução dos custos e aumento da velocidade no mercado. Centenas de milhões de assinantes confiam nos produtos da Synchronoss que se mantêm em sincronia com as pessoas, serviços e conteúdo que elas gostam. É por isso que mais de 1.500 funcionários talentosos da Synchronoss em todo o mundo se esforçam todos os dias para reimaginar um mundo em sincronia. Saiba mais em www.synchronoss.com

Contato de Relações com a Mídia:
Domenick Cilea
Springboard
dcilea@springboardpr.com

Contato de Relações com Investidores:
Matt Glover / Tom Colton
Gateway Group, Inc.
SNCR@gatewayir.com